Controlling Shareholder Randal J. Kirk Sells $15.6M in Precigen Stock, Reducing Stake
PGEN has more than doubled off its 52-week low of $1.11 on elevated volume (2.7× avg).
Summary
Randal J. Kirk, the controlling shareholder of Precigen, Inc., through affiliated entities, sold 4.77 million shares of common stock for approximately $15.6 million, reducing his beneficial ownership from approximately 37.2% to 35.9%.
Key Events · Ownership and Investor Activity · PGEN
-
Significant Share Sale
Entities controlled by Randal J. Kirk sold 4,772,781 shares of Precigen common stock in open market transactions on March 30, 2026.
-
Substantial Proceeds
The sale generated approximately $15,581,221 in net proceeds for the selling entities.
-
Reduced Ownership Stake
This transaction decreased Randal J. Kirk's beneficial ownership from approximately 37.2% to 35.9% of the company's outstanding shares (including exercisable derivatives).
Analysis · PGEN · Life Sciences
This Schedule 13D/A reports a significant disposition of shares by Randal J. Kirk, the company's controlling shareholder. The sale of over $15.5 million worth of stock, representing approximately 1.14% of the company's market capitalization, is a material event. While the filing notes Kirk's continued beneficial ownership of 35.9% (including exercisable warrants and options), this reduction in his stake could be interpreted by investors as a signal, especially following the recent 10-K filing which reported a substantial net loss for 2025. Investors will likely monitor future filings for further changes in insider holdings.
At the time of this filing, PGEN was trading at $3.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $1.11 to $5.47. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.